Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma

A stage-matched comparison of outcomes

Nabil Wasif, David J. Bentrem, James J. Farrell, Clifford Y. Ko, Oscar J. Hines, Howard A. Reber, James S. Tomlinson

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

BACKGROUND: Although invasive intraductal papillary mucinous neoplasm (IPMN) of the pancreas is thought to be more indolent than sporadic pancreatic adenocarcinoma (PAC), the natural history remains poorly defined. The authors compared survival and identify prognostic factors after resection for invasive IPMN versus stage-matched PAC. METHODS: The Surveillance, Epidemiology, and End Results database (1991-2005) was used to identify 729 patients with invasive IPMN and 8082 patients with PAC who underwent surgical resection. RESULTS: Patients with resected invasive IPMN experienced improved overall survival when compared with resected PAC (median survival, 21 vs 14 months; P < .001). Stratification by nodal status demonstrated no difference in survival among lymph node-positive patients; however, median survival of resected, lymph node-negative, invasive IPMN was significantly improved compared with lymph node-negative PAC (34 vs 18 months; P < .001). On multivariate analysis, PAC histology was an adverse predictor of overall survival (hazard ratio [HR], 1.31; 95% confidence interval [CI], 1.15-1.50) compared with invasive IPMN. For patients with invasive IPMN, positive lymph nodes (HR, 1.98; 95% CI, 1.50-2.60), high tumor grade (HR, 1.74; 95% CI, 1.31-2.31), tumor size >2 cm (HR, 1.50; 95% CI, 1.04-2.19), and age >66 years (HR, 1.33; 95% CI, 1.03-1.73) were adverse predictors of survival. CONCLUSIONS: Although lymph node-negative invasive IPMN showed improved survival after resection compared with lymph node-negative PAC, the natural history of lymph node-positive invasive IPMN mimicked that of lymph node-positive PAC. The authors also identified adverse predictors of survival in invasive IPMN to guide discussions regarding use of adjuvant therapies and prognosis after resection of invasive IPMN.

Original languageEnglish (US)
Pages (from-to)3369-3377
Number of pages9
JournalCancer
Volume116
Issue number14
DOIs
StatePublished - Jul 15 2010
Externally publishedYes

Fingerprint

Adenocarcinoma
Survival
Lymph Nodes
Neoplasms
Natural History
Pancreatic Neoplasms
Epidemiology
Databases

Keywords

  • Intraductal papillary mucinous neoplasm
  • Outcomes
  • Pancreatic cancer
  • Stage-matched
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Wasif, N., Bentrem, D. J., Farrell, J. J., Ko, C. Y., Hines, O. J., Reber, H. A., & Tomlinson, J. S. (2010). Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: A stage-matched comparison of outcomes. Cancer, 116(14), 3369-3377. https://doi.org/10.1002/cncr.25070

Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma : A stage-matched comparison of outcomes. / Wasif, Nabil; Bentrem, David J.; Farrell, James J.; Ko, Clifford Y.; Hines, Oscar J.; Reber, Howard A.; Tomlinson, James S.

In: Cancer, Vol. 116, No. 14, 15.07.2010, p. 3369-3377.

Research output: Contribution to journalArticle

Wasif, Nabil ; Bentrem, David J. ; Farrell, James J. ; Ko, Clifford Y. ; Hines, Oscar J. ; Reber, Howard A. ; Tomlinson, James S. / Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma : A stage-matched comparison of outcomes. In: Cancer. 2010 ; Vol. 116, No. 14. pp. 3369-3377.
@article{484f390004574a8f8985e280da39ac4b,
title = "Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: A stage-matched comparison of outcomes",
abstract = "BACKGROUND: Although invasive intraductal papillary mucinous neoplasm (IPMN) of the pancreas is thought to be more indolent than sporadic pancreatic adenocarcinoma (PAC), the natural history remains poorly defined. The authors compared survival and identify prognostic factors after resection for invasive IPMN versus stage-matched PAC. METHODS: The Surveillance, Epidemiology, and End Results database (1991-2005) was used to identify 729 patients with invasive IPMN and 8082 patients with PAC who underwent surgical resection. RESULTS: Patients with resected invasive IPMN experienced improved overall survival when compared with resected PAC (median survival, 21 vs 14 months; P < .001). Stratification by nodal status demonstrated no difference in survival among lymph node-positive patients; however, median survival of resected, lymph node-negative, invasive IPMN was significantly improved compared with lymph node-negative PAC (34 vs 18 months; P < .001). On multivariate analysis, PAC histology was an adverse predictor of overall survival (hazard ratio [HR], 1.31; 95{\%} confidence interval [CI], 1.15-1.50) compared with invasive IPMN. For patients with invasive IPMN, positive lymph nodes (HR, 1.98; 95{\%} CI, 1.50-2.60), high tumor grade (HR, 1.74; 95{\%} CI, 1.31-2.31), tumor size >2 cm (HR, 1.50; 95{\%} CI, 1.04-2.19), and age >66 years (HR, 1.33; 95{\%} CI, 1.03-1.73) were adverse predictors of survival. CONCLUSIONS: Although lymph node-negative invasive IPMN showed improved survival after resection compared with lymph node-negative PAC, the natural history of lymph node-positive invasive IPMN mimicked that of lymph node-positive PAC. The authors also identified adverse predictors of survival in invasive IPMN to guide discussions regarding use of adjuvant therapies and prognosis after resection of invasive IPMN.",
keywords = "Intraductal papillary mucinous neoplasm, Outcomes, Pancreatic cancer, Stage-matched, Survival",
author = "Nabil Wasif and Bentrem, {David J.} and Farrell, {James J.} and Ko, {Clifford Y.} and Hines, {Oscar J.} and Reber, {Howard A.} and Tomlinson, {James S.}",
year = "2010",
month = "7",
day = "15",
doi = "10.1002/cncr.25070",
language = "English (US)",
volume = "116",
pages = "3369--3377",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "14",

}

TY - JOUR

T1 - Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma

T2 - A stage-matched comparison of outcomes

AU - Wasif, Nabil

AU - Bentrem, David J.

AU - Farrell, James J.

AU - Ko, Clifford Y.

AU - Hines, Oscar J.

AU - Reber, Howard A.

AU - Tomlinson, James S.

PY - 2010/7/15

Y1 - 2010/7/15

N2 - BACKGROUND: Although invasive intraductal papillary mucinous neoplasm (IPMN) of the pancreas is thought to be more indolent than sporadic pancreatic adenocarcinoma (PAC), the natural history remains poorly defined. The authors compared survival and identify prognostic factors after resection for invasive IPMN versus stage-matched PAC. METHODS: The Surveillance, Epidemiology, and End Results database (1991-2005) was used to identify 729 patients with invasive IPMN and 8082 patients with PAC who underwent surgical resection. RESULTS: Patients with resected invasive IPMN experienced improved overall survival when compared with resected PAC (median survival, 21 vs 14 months; P < .001). Stratification by nodal status demonstrated no difference in survival among lymph node-positive patients; however, median survival of resected, lymph node-negative, invasive IPMN was significantly improved compared with lymph node-negative PAC (34 vs 18 months; P < .001). On multivariate analysis, PAC histology was an adverse predictor of overall survival (hazard ratio [HR], 1.31; 95% confidence interval [CI], 1.15-1.50) compared with invasive IPMN. For patients with invasive IPMN, positive lymph nodes (HR, 1.98; 95% CI, 1.50-2.60), high tumor grade (HR, 1.74; 95% CI, 1.31-2.31), tumor size >2 cm (HR, 1.50; 95% CI, 1.04-2.19), and age >66 years (HR, 1.33; 95% CI, 1.03-1.73) were adverse predictors of survival. CONCLUSIONS: Although lymph node-negative invasive IPMN showed improved survival after resection compared with lymph node-negative PAC, the natural history of lymph node-positive invasive IPMN mimicked that of lymph node-positive PAC. The authors also identified adverse predictors of survival in invasive IPMN to guide discussions regarding use of adjuvant therapies and prognosis after resection of invasive IPMN.

AB - BACKGROUND: Although invasive intraductal papillary mucinous neoplasm (IPMN) of the pancreas is thought to be more indolent than sporadic pancreatic adenocarcinoma (PAC), the natural history remains poorly defined. The authors compared survival and identify prognostic factors after resection for invasive IPMN versus stage-matched PAC. METHODS: The Surveillance, Epidemiology, and End Results database (1991-2005) was used to identify 729 patients with invasive IPMN and 8082 patients with PAC who underwent surgical resection. RESULTS: Patients with resected invasive IPMN experienced improved overall survival when compared with resected PAC (median survival, 21 vs 14 months; P < .001). Stratification by nodal status demonstrated no difference in survival among lymph node-positive patients; however, median survival of resected, lymph node-negative, invasive IPMN was significantly improved compared with lymph node-negative PAC (34 vs 18 months; P < .001). On multivariate analysis, PAC histology was an adverse predictor of overall survival (hazard ratio [HR], 1.31; 95% confidence interval [CI], 1.15-1.50) compared with invasive IPMN. For patients with invasive IPMN, positive lymph nodes (HR, 1.98; 95% CI, 1.50-2.60), high tumor grade (HR, 1.74; 95% CI, 1.31-2.31), tumor size >2 cm (HR, 1.50; 95% CI, 1.04-2.19), and age >66 years (HR, 1.33; 95% CI, 1.03-1.73) were adverse predictors of survival. CONCLUSIONS: Although lymph node-negative invasive IPMN showed improved survival after resection compared with lymph node-negative PAC, the natural history of lymph node-positive invasive IPMN mimicked that of lymph node-positive PAC. The authors also identified adverse predictors of survival in invasive IPMN to guide discussions regarding use of adjuvant therapies and prognosis after resection of invasive IPMN.

KW - Intraductal papillary mucinous neoplasm

KW - Outcomes

KW - Pancreatic cancer

KW - Stage-matched

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=77954904476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954904476&partnerID=8YFLogxK

U2 - 10.1002/cncr.25070

DO - 10.1002/cncr.25070

M3 - Article

VL - 116

SP - 3369

EP - 3377

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 14

ER -